89bio (ETNB) Revenue & Revenue Breakdown
89bio Revenue Highlights
89bio Revenue by Period
89bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
89bio generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
89bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $234.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | - |
89bio generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
89bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| ACLX | Arcellx | $110.32M | $27.38M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| VKTX | Viking Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ETNB | 89bio | - | - |
| AKRO | Akero Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
ETNB Revenue FAQ
What is 89bio’s yearly revenue?
89bio's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ETNB's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is 89bio’s quarterly revenue?
89bio's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ETNB's quarterly revenue for Q4 2023 was $234K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is 89bio’s revenue growth rate?
89bio's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.